Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303031 | 0.82 | HRH3 (0.53) | ATMHTTALDH1A1GPR119MAPT | |
| SCHEMBL15876877 | 0.82 | ALDH1A1 (0.44) | ATMHTTALDH1A1GPR119MAPT | |
| SCHEMBL18702081 | 0.82 | ATM (0.50) | ATMPHGDHHTTALDH1A1MAPT | |
| SCHEMBL30329292 | 0.82 | CYP11B2 (0.44) | ATMHTTSPR | |
| SCHEMBL18711350 | 0.82 | ATM (0.52) | ATMPHGDHHTTALDH1A1MAPT | |
| SCHEMBL7481716 | 0.81 | ALDH1A1 (0.47) | ATMHTTALDH1A1GPR119MAPT | |
| SCHEMBL28772014 | 0.79 | ATM (0.47) | ATMPHGDHHTTALDH1A1MEN1 | |
| SCHEMBL30328604 | 0.79 | USP30 (0.45) | GPR119MAPTUSP2SMN1; SMN2 | |
| SCHEMBL3788500 | 0.78 | EGLN2 (0.43) | ATMHTTALDH1A1GPR119MAPT | |
| SCHEMBL2824232 | 0.77 | CKS1B (0.48) | ALDH1A1GPR119MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1838308-A1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | ATM 1953/4885PHGDH 1596/4885HTT 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.